given
scale
rapid
spread
novel
coronaviru
acut
respiratori
diseas
immedi
need
medicin
help
vaccin
produc
result
rapid
sequenc
coupl
molecular
model
base
genom
relat
viru
protein
suggest
compound
like
effect
includ
antihiv
lopinavir
plu
ritonavir
combin
benevolentai
knowledg
graph
larg
repositori
structur
medic
inform
includ
numer
connect
extract
scientif
literatur
machin
learn
togeth
customis
bespok
use
benevolentai
search
approv
drug
could
help
focus
might
block
viral
infect
process
identifi
baricitinib
predict
reduc
abil
viru
infect
lung
cell
virus
enter
cell
receptormedi
endocytosi
receptor
use
infect
lung
cell
might
cellsurfac
protein
cell
kidney
blood
vessel
heart
importantli
lung
alveolar
epitheli
cell
figur
cell
particularli
prone
viral
infect
one
known
regul
endocytosi
protein
kinas
disrupt
might
turn
interrupt
passag
viru
cell
also
intracellular
assembl
viru
particl
inhibitor
knowledg
graph
approv
medic
use
six
inhibit
high
affin
includ
number
oncolog
drug
sunitinib
erlotinib
shown
inhibit
viral
infect
cell
inhibit
howev
compound
bring
seriou
sideeffect
data
infer
high
dose
inhibit
effect
consid
drug
would
safe
therapi
popul
sick
infect
peopl
contrast
one
six
highaffin
drug
janu
kinas
inhibitor
baricitinib
also
bind
cyclin
gassoci
kinas
anoth
regul
endocytosi
plasma
concentr
baricitinib
therapeut
dose
either
mg
mg
daili
suffici
inhibit
suggest
could
triall
use
appropri
patient
popul
acut
respiratori
diseas
reduc
viral
entri
inflamm
patient
use
endpoint
mulbsta
score
earli
warn
model
predict
mortal
viral
pneumonia
js
editorinchief
oncogen
js
previous
sat
number
scientif
advisori
board
includ
benevolentai
consult
lansdown
partner
vitruvian
social
impact
capit
sit
board
director
bb
biotech
healthcar
trust
chair
xerion
healthcar
author
employe
benevolentai
event
relat
outbreak
evolv
rapidli
make
initi
thought
avail
correspond
good
faith
assist
global
respons
earli
investig
suggest
requir
detail
work
analysi
reli
constitut
kind
medic
advic
recommend
